CA983033A - 2-amino-1,4-dihydropyridine derivatives - Google Patents

2-amino-1,4-dihydropyridine derivatives

Info

Publication number
CA983033A
CA983033A CA165,210A CA165210A CA983033A CA 983033 A CA983033 A CA 983033A CA 165210 A CA165210 A CA 165210A CA 983033 A CA983033 A CA 983033A
Authority
CA
Canada
Prior art keywords
amino
dihydropyridine derivatives
dihydropyridine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA165,210A
Other languages
English (en)
Other versions
CA165210S (en
Inventor
Kurt Stoepel
Friedrich Bossert
Wulf Vater
Horst Meyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Application granted granted Critical
Publication of CA983033A publication Critical patent/CA983033A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
CA165,210A 1972-03-06 1973-03-05 2-amino-1,4-dihydropyridine derivatives Expired CA983033A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2210674A DE2210674C3 (de) 1972-03-06 1972-03-06 2-Amino-6-methyl-1,4-dihydropyridine, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
CA983033A true CA983033A (en) 1976-02-03

Family

ID=5838026

Family Applications (1)

Application Number Title Priority Date Filing Date
CA165,210A Expired CA983033A (en) 1972-03-06 1973-03-05 2-amino-1,4-dihydropyridine derivatives

Country Status (27)

Country Link
US (1) US3867393A (ja)
JP (2) JPS5720306B2 (ja)
AT (1) AT324337B (ja)
AU (1) AU468090B2 (ja)
BE (1) BE796278A (ja)
BG (1) BG23213A3 (ja)
CA (1) CA983033A (ja)
CH (1) CH580590A5 (ja)
DD (1) DD107274A5 (ja)
DE (1) DE2210674C3 (ja)
DK (1) DK136214C (ja)
ES (1) ES412322A1 (ja)
FI (1) FI56681C (ja)
FR (1) FR2183675B1 (ja)
GB (1) GB1369401A (ja)
HK (1) HK44977A (ja)
HU (1) HU167087B (ja)
IE (1) IE37369B1 (ja)
IL (1) IL41665A (ja)
LU (1) LU67148A1 (ja)
NL (1) NL7303136A (ja)
NO (1) NO140977C (ja)
PL (1) PL89258B1 (ja)
RO (1) RO61193A (ja)
SE (1) SE384207B (ja)
YU (1) YU44873A (ja)
ZA (1) ZA731503B (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959296A (en) * 1972-06-10 1976-05-25 Bayer Aktiengesellschaft 1,4-Dihydropyridines
US3974278A (en) * 1973-07-12 1976-08-10 Bayer Aktiengesellschaft 1,4-Dihydropyridine esters
CH607848A5 (ja) * 1974-06-04 1978-11-30 Bayer Ag
US4177278A (en) * 1977-04-05 1979-12-04 Bayer Aktiengesellschaft 2-Alkyleneaminodihydropyridines compounds, their production and their medicinal use
DE2715182A1 (de) * 1977-04-05 1978-10-19 Bayer Ag 2-alkylenaminodihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
FI813460L (fi) * 1980-11-10 1982-05-11 Sandoz Ag Nya 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-pyridinderivat deras framstaellningsfoerfarande och dessa innehaollande farmaceutiska kompositioner
DE3208628A1 (de) * 1982-03-10 1983-09-22 Bayer Ag, 5090 Leverkusen Neue verbindungen, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
EP0125803A3 (en) * 1983-04-27 1987-01-21 FISONS plc Pharmaceutically active dihydropyridines
US4603135A (en) * 1983-10-17 1986-07-29 Takeda Chemical Industries, Ltd. Substituted piperazinyl alkyl esters of 2-amino-4-aryl-1,4-dihydro-6-alkyl-3,5-pyridinedicarboxylates
GB8620880D0 (en) * 1986-08-29 1986-10-08 Pfizer Ltd Therapeutic agents
US4912239A (en) * 1987-11-13 1990-03-27 Dow Corning Corporation Method for stabilizing unsaturated organosilicone compositions
US5455253A (en) * 1992-10-20 1995-10-03 Zeneca Limited Heterocyclic derivatives
DE4430095A1 (de) * 1994-08-25 1996-02-29 Bayer Ag Verwendung von 6-Amino-1,4-dihydropyridinen als Arzneimittel zur Behandlung des zentralen Nervensystems und Verfahren zu ihrer Herstellung
DE4444860A1 (de) * 1994-12-16 1996-06-20 Bayer Ag Verwendung von 1,2-überbrückten 1,4-Dihydropyridinen als Arzneimittel
AU2004272078A1 (en) * 2003-09-10 2005-03-24 Synta Pharmaceuticals Corp. Dihydropyridine compounds for treating or preventing metabolic disorders
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3325505A (en) * 1965-02-24 1967-06-13 Smith Kline French Lab 4-cycloalkyl(or cycloalkenyl)-dihydropyridines
US3511847A (en) * 1967-02-07 1970-05-12 Smithkline Corp 2,6-di-lower alkyl - 1,4-dihydro - 4-(2-trifluoromethylphenyl) - 3,5 - pyridinedicarboxylic acid esters
DE1923990C3 (de) * 1969-05-10 1978-11-23 Bayer Ag Verfahren zur Herstellung von N-substituierten M-Dihydropyridin-S.S-dicarbonsäureestern
DE2013431C3 (de) * 1970-03-20 1979-12-20 Bayer Ag, 5090 Leverkusen 4-Azidophenyl-l,4-dihydropyridin-3,5-dicarbonsäureester
DE1963186C3 (de) * 1969-12-17 1979-02-15 Bayer Ag, 5090 Leverkusen Schwefelhaltige 1,4-Dihydropyridin-33-dicarbonsäureester
DE1963188A1 (de) * 1969-12-17 1971-06-24 Bayer Ag Neue Cyanphenyl-1,4-dihydropyridinderivate
ZA7152B (en) * 1970-01-24 1971-10-27 Bayer Ag New pharmaceutically active 1,4-dihydropyridines
DE2117572C3 (de) * 1971-04-10 1980-03-20 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin ^-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
DE2117571C3 (de) * 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
NO140977C (no) 1979-12-19
IE37369B1 (en) 1977-07-06
NO140977B (no) 1979-09-10
IL41665A (en) 1975-08-31
SE384207B (sv) 1976-04-26
YU44873A (en) 1982-02-25
FI56681C (fi) 1980-03-10
AU5287573A (en) 1975-03-27
AU468090B2 (en) 1975-03-27
LU67148A1 (ja) 1973-05-22
DE2210674B2 (de) 1980-09-04
JPS5798265A (en) 1982-06-18
BG23213A3 (ja) 1977-07-12
DE2210674A1 (de) 1973-09-13
US3867393A (en) 1975-02-18
CH580590A5 (ja) 1976-10-15
FR2183675A1 (ja) 1973-12-21
NL7303136A (ja) 1973-09-10
BE796278A (fr) 1973-09-05
ES412322A1 (es) 1976-01-01
DE2210674C3 (de) 1981-09-24
PL89258B1 (ja) 1976-11-30
IE37369L (en) 1973-09-06
JPS5720306B2 (ja) 1982-04-27
RO61193A (ja) 1976-10-15
DK136214C (da) 1978-03-06
HU167087B (ja) 1975-08-28
FR2183675B1 (ja) 1976-12-03
DD107274A5 (ja) 1974-07-20
DK136214B (da) 1977-09-05
HK44977A (en) 1977-09-09
GB1369401A (en) 1974-10-09
FI56681B (fi) 1979-11-30
IL41665A0 (en) 1973-05-31
ZA731503B (en) 1973-11-28
JPS48103586A (ja) 1973-12-25
AT324337B (de) 1975-08-25

Similar Documents

Publication Publication Date Title
CA1003417A (en) Piperidine derivatives
CA999589A (en) 2,2,6,6-tetramethylpiperidinyl-4-acetic acid derivatives
CA983033A (en) 2-amino-1,4-dihydropyridine derivatives
CA1012534A (en) 2,6-diaminonebularine derivatives
AU467361B2 (en) Q-aryl-4-substituted piperidinoalkanol derivatives
CA999588A (en) 2,2,6,6-tetramethylpiperidinyl-4-acetic acid derivatives
CA999869A (en) Process for the preparation of 2-amino-1,4-dihydropyridine derivatives
CA1019733A (en) Pyrimidino-dibenzo-azepine, dibenzo-oxazepine, -thiazepine and -diazepine derivatives
CA1019738A (en) Isothiocyanopyridine derivatives
AU470719B2 (en) Oxazinoindole-and thiazinoinindole derivatives
CA1020946A (en) 1-phenoxy-3-phenoxyethylamino-2-propanol derivatives
AU467405B2 (en) Diphenylalkyllactamimide derivatives
CA1010036A (en) 2,2,6,6-tetramethylpiperidinyl-4-acetic acid derivatives
CA1018161A (en) Indan-1-carboxamide derivatives
AU470763B2 (en) Pyrano-and thiopyranoindole derivatives
CA1006514A (en) Beta-aminoketone derivatives
CA978526A (en) Pyrano- and thiopyranoindole derivatives
AU469505B2 (en) 1,4-ethano-2,3-dihydroquinoline derivatives
CA981684A (en) Cyclopenteno-quinolone derivatives
CA959054A (en) 2,3-benzoxazepine derivatives
CA891497A (en) Piperidine derivatives
CA899353A (en) 1-hydroxyproline derivatives
AU482792B2 (en) Indan-1-carboxamide derivatives
CA901015A (en) Benzophenonimine derivatives
CA1012557A (en) 2-amino-1-phenyl-butane derivatives